From the latest vaccination evidence, recommendations, and protocols . . . to new vaccine development and the use of vaccines in reducing disease, Plotkin’s Vaccines, 8th Edition, covers every aspect of vaccination. Now completely revised and updated from cover to cover, this award-winning text continues to provide reliable information from global authorities, offering a complete understanding of each disease, as well as the latest knowledge of both existing vaccines and those currently in research and development. Described by Bill Gates as "an indispensable guide to the enhancement of the well-being of our world," Plotkin’s Vaccines is a must-have reference for current, authoritative information in this fast-moving field.
1. Cover Image - p. i 2. Title Page - p. iii 3. Copyright - p. iv 4. Dedication - p. v 5. Contributors - p. vi 6. Foreword - p. xv 7. Preface to the First Edition - p. xvii 8. Preface to the Eighth Edition - p. xviii 9. Acknowledgments - p. xx 10. Table of Contents - p. xxi 11. Multimedia Resources - p. xxi 12. Section I General Aspects of Vaccination - p. xxi 13. Chapter 1 A Short History of Vaccination - p. 1 14. Chapter 2 Vaccine Immunology - p. 17 15. Chapter 3 Non-specific Effects of Vaccines - p. 37 16. Chapter 4 Correlates of Protection - p. 45 17. Chapter 5 The Vaccine Industry - p. 52 18. Chapter 6 Vaccine Manufacturing - p. 64 19. Chapter 7 Evolution of Adjuvants Across the Centuries - p. 77 20. Chapter 8 Vaccine Additives and Manufacturing Residuals in Vaccines Licensed in the United States - p. 91 21. Chapter 9 Passive Immunization - p. 100 22. Section II Licenced Vaccines and Vaccines in Development - p. 112.e11 23. Chapter 10 General Immunization Practices - p. 113 24. Chapter 11 Human Adenovirus Vaccines - p. 145 25. Chapter 12 Anthrax Vaccines - p. 157 26. Chapter 13 Biodefense Vaccines, Vaccines for Emerging Infectious Diseases, and Coalition for Epidemic Preparedness Innovations (CEPI) - p. 172 27. Chapter 14 Cancer Vaccines - p. 191 28. Chapter 15 Cholera Vaccines - p. 211 29. Chapter 16 Combination Vaccines - p. 225 30. Chapter 17 Coronavirus Vaccines - p. 248 31. Chapter 18 Cytomegalovirus Vaccines - p. 258 32. Chapter 19 Dengue Vaccines - p. 275 33. Chapter 20 Vaccines Against Diarrhea Caused by Noncholera Bacteria - p. 286 34. Chapter 21 Diphtheria Toxoid - p. 298 35. Chapter 22 Ebola Vaccines - p. 311 36. Chapter 23 Nonpolio Enteroviruses - p. 330 37. Chapter 24 Epstein–Barr Virus Vaccines - p. 341 38. Chapter 25 Haemophilus influenzae Type b Vaccines - p. 348 39. Chapter 26 Hepatitis A Vaccines - p. 365 40. Chapter 27 Hepatitis B Vaccines - p. 389 41. Chapter 28 Hepatitis C Vaccines - p. 433 42. Chapter 29 Hepatitis E Vaccines - p. 443 43. Chapter 30 Herpes Simplex Virus Vaccines - p. 451 44. Chapter 31 Human Immunodeficiency Virus Vaccines - p. 458 45. Chapter 32 Human Papillomavirus Vaccines - p. 484 46. Chapter 33 Inactivated and Recombinant Influenza Vaccines - p. 514 47. Chapter 34 Influenza Vaccine—Live - p. 552 48. Chapter 35 Japanese Encephalitis Vaccines - p. 577 49. Chapter 36 Lyme Disease Vaccines—The Journey Continues - p. 608 50. Chapter 37 Malaria Vaccines - p. 617 51. Online Supplements - p. 628.e8 52. Chapter 38 Measles Vaccines - p. 629 53. Chapter 39 Meningococcal Capsular Group A, C, W, and Y Conjugate Vaccines - p. 664 54. Chapter 40 Meningococcal Vaccines Directed at Capsular Group B - p. 690 55. Chapter 41 Mumps Vaccines - p. 711 56. Chapter 42 Noninfectious Disease Vaccines - p. 736 57. Chapter 43 Norovirus - p. 747 58. Chapter 44 Parasitic Disease Vaccines - p. 755 59. Chapter 45 Pertussis Vaccines - p. 763 60. Chapter 46 Plague Vaccines - p. 816 61. Chapter 47 Pneumococcal Conjugate Vaccine and Pneumococcal Common Protein Vaccines - p. 826 62. Chapter 48 Pneumococcal Polysaccharide Vaccines - p. 869 63. Chapter 49 Poliovirus Vaccine—Inactivated - p. 890 64. Chapter 50 Poliovirus Vaccine–Live - p. 914 65. Chapter 51 Lyssaviruses and Rabies Vaccines - p. 969 66. Chapter 52 Respiratory Syncytial Virus Vaccines and Monoclonal Antibodies - p. 998 67. Chapter 53 Rotavirus Vaccines - p. 1005 68. Chapter 54 Rubella Vaccines - p. 1025 69. Chapter 55 Smallpox and Vaccinia - p. 1057 70. Chapter 56 Staphylococcus aureus Vaccines - p. 1087 71. Chapter 57 Streptococcus Group A Vaccines - p. 1095 72. Chapter 58 Streptococcus Group B Vaccines - p. 1104 73. Chapter 59 Tetanus Toxoid - p. 1117 74. Chapter 60 Tickborne Encephalitis Vaccines - p. 1142 75. Chapter 61 Tuberculosis Vaccines - p. 1158 76. Chapter 62 Typhoid Fever Vaccines - p. 1177 77. Chapter 63 Varicella Vaccines - p. 1215 78. Chapter 64 Yellow Fever Vaccine - p. 1251 79. Chapter 65 Zika Virus Vaccines - p. 1322 80. Chapter 66 Zoster Vaccines - p. 1334 81. Section III New Technologies - p. 1349.e7 82. Chapter 67 Technologies for Making New Vaccines - p. 1350 83. Chapter 68 Genetic-Based Vaccine Vectors - p. 1374 84. Chapter 69 Technologies to Improve Immunization - p. 1397 85. Section IV Vaccination of Special Groups - p. 1431.e18 86. Chapter 70 Vaccination of Immunocompromised Hosts - p. 1432 87. Chapter 71 Vaccines for International Travel - p. 1450 88. Chapter 72 Vaccines for Healthcare Personnel - p. 1469 89. Chapter 73 Vaccination of Pregnant Women - p. 1489 90. Section V Public Health and Regulatory Issues - p. 1502.e6 91. Chapter 74 Immunization in the United States - p. 1503 92. Chapter 75 Immunization in Europe - p. 1523 93. Chapter 76 Immunization and Vaccine-Preventable Diseases in the Asia-Pacific Region - p. 1560 94. Chapter 77 Immunization in Low- and Middle-Income Countries - p. 1578 95. Chapter 78 Community Protection - p. 1603 96. Chapter 79 Economic Analyses of Vaccine Policies - p. 1625 97. Chapter 80 Regulation and Testing of Vaccines in the US - p. 1640 98. Chapter 81 Regulation of Vaccines in Europe - p. 1660 99. Chapter 82 Regulation of Vaccines in Low- and Middle-Income Countries - p. 1671 100. Chapter 83 Vaccine Safety - p. 1679 101. Chapter 84 Vaccine Hesitancy and Behavioral Factors Associated With Vaccine Uptake - p. 1696 102. Chapter 85 Legal Issues - p. 1704 103. Chapter 86 Ethics - p. 1738 104. Chapter 87 Vaccines to Prevent Mpox - p. e.1 105. Appendix Websites and Applications for Mobile Devices With Information About Immunization - p. 1745 106. Index - p. 1752
From the latest vaccination evidence, recommendations, and protocols . . . to new vaccine development and the use of vaccines in reducing disease, Plotkin’s Vaccines, 8th Edition, covers every aspect of vaccination. Now completely revised and updated from cover to cover, this award-winning text continues to provide reliable information from global authorities, offering a complete understanding of each disease, as well as the latest knowledge of both existing vaccines and those currently in research and development. Described by Bill Gates as "an indispensable guide to the enhancement of the well-being of our world," Plotkin’s Vaccines is a must-have reference for current, authoritative information in this fast-moving field.
1. Cover Image - p. i 2. Title Page - p. iii 3. Copyright - p. iv 4. Dedication - p. v 5. Contributors - p. vi 6. Foreword - p. xv 7. Preface to the First Edition - p. xvii 8. Preface to the Eighth Edition - p. xviii 9. Acknowledgments - p. xx 10. Table of Contents - p. xxi 11. Multimedia Resources - p. xxi 12. Section I General Aspects of Vaccination - p. xxi 13. Chapter 1 A Short History of Vaccination - p. 1 14. Chapter 2 Vaccine Immunology - p. 17 15. Chapter 3 Non-specific Effects of Vaccines - p. 37 16. Chapter 4 Correlates of Protection - p. 45 17. Chapter 5 The Vaccine Industry - p. 52 18. Chapter 6 Vaccine Manufacturing - p. 64 19. Chapter 7 Evolution of Adjuvants Across the Centuries - p. 77 20. Chapter 8 Vaccine Additives and Manufacturing Residuals in Vaccines Licensed in the United States - p. 91 21. Chapter 9 Passive Immunization - p. 100 22. Section II Licenced Vaccines and Vaccines in Development - p. 112.e11 23. Chapter 10 General Immunization Practices - p. 113 24. Chapter 11 Human Adenovirus Vaccines - p. 145 25. Chapter 12 Anthrax Vaccines - p. 157 26. Chapter 13 Biodefense Vaccines, Vaccines for Emerging Infectious Diseases, and Coalition for Epidemic Preparedness Innovations (CEPI) - p. 172 27. Chapter 14 Cancer Vaccines - p. 191 28. Chapter 15 Cholera Vaccines - p. 211 29. Chapter 16 Combination Vaccines - p. 225 30. Chapter 17 Coronavirus Vaccines - p. 248 31. Chapter 18 Cytomegalovirus Vaccines - p. 258 32. Chapter 19 Dengue Vaccines - p. 275 33. Chapter 20 Vaccines Against Diarrhea Caused by Noncholera Bacteria - p. 286 34. Chapter 21 Diphtheria Toxoid - p. 298 35. Chapter 22 Ebola Vaccines - p. 311 36. Chapter 23 Nonpolio Enteroviruses - p. 330 37. Chapter 24 Epstein–Barr Virus Vaccines - p. 341 38. Chapter 25 Haemophilus influenzae Type b Vaccines - p. 348 39. Chapter 26 Hepatitis A Vaccines - p. 365 40. Chapter 27 Hepatitis B Vaccines - p. 389 41. Chapter 28 Hepatitis C Vaccines - p. 433 42. Chapter 29 Hepatitis E Vaccines - p. 443 43. Chapter 30 Herpes Simplex Virus Vaccines - p. 451 44. Chapter 31 Human Immunodeficiency Virus Vaccines - p. 458 45. Chapter 32 Human Papillomavirus Vaccines - p. 484 46. Chapter 33 Inactivated and Recombinant Influenza Vaccines - p. 514 47. Chapter 34 Influenza Vaccine—Live - p. 552 48. Chapter 35 Japanese Encephalitis Vaccines - p. 577 49. Chapter 36 Lyme Disease Vaccines—The Journey Continues - p. 608 50. Chapter 37 Malaria Vaccines - p. 617 51. Online Supplements - p. 628.e8 52. Chapter 38 Measles Vaccines - p. 629 53. Chapter 39 Meningococcal Capsular Group A, C, W, and Y Conjugate Vaccines - p. 664 54. Chapter 40 Meningococcal Vaccines Directed at Capsular Group B - p. 690 55. Chapter 41 Mumps Vaccines - p. 711 56. Chapter 42 Noninfectious Disease Vaccines - p. 736 57. Chapter 43 Norovirus - p. 747 58. Chapter 44 Parasitic Disease Vaccines - p. 755 59. Chapter 45 Pertussis Vaccines - p. 763 60. Chapter 46 Plague Vaccines - p. 816 61. Chapter 47 Pneumococcal Conjugate Vaccine and Pneumococcal Common Protein Vaccines - p. 826 62. Chapter 48 Pneumococcal Polysaccharide Vaccines - p. 869 63. Chapter 49 Poliovirus Vaccine—Inactivated - p. 890 64. Chapter 50 Poliovirus Vaccine–Live - p. 914 65. Chapter 51 Lyssaviruses and Rabies Vaccines - p. 969 66. Chapter 52 Respiratory Syncytial Virus Vaccines and Monoclonal Antibodies - p. 998 67. Chapter 53 Rotavirus Vaccines - p. 1005 68. Chapter 54 Rubella Vaccines - p. 1025 69. Chapter 55 Smallpox and Vaccinia - p. 1057 70. Chapter 56 Staphylococcus aureus Vaccines - p. 1087 71. Chapter 57 Streptococcus Group A Vaccines - p. 1095 72. Chapter 58 Streptococcus Group B Vaccines - p. 1104 73. Chapter 59 Tetanus Toxoid - p. 1117 74. Chapter 60 Tickborne Encephalitis Vaccines - p. 1142 75. Chapter 61 Tuberculosis Vaccines - p. 1158 76. Chapter 62 Typhoid Fever Vaccines - p. 1177 77. Chapter 63 Varicella Vaccines - p. 1215 78. Chapter 64 Yellow Fever Vaccine - p. 1251 79. Chapter 65 Zika Virus Vaccines - p. 1322 80. Chapter 66 Zoster Vaccines - p. 1334 81. Section III New Technologies - p. 1349.e7 82. Chapter 67 Technologies for Making New Vaccines - p. 1350 83. Chapter 68 Genetic-Based Vaccine Vectors - p. 1374 84. Chapter 69 Technologies to Improve Immunization - p. 1397 85. Section IV Vaccination of Special Groups - p. 1431.e18 86. Chapter 70 Vaccination of Immunocompromised Hosts - p. 1432 87. Chapter 71 Vaccines for International Travel - p. 1450 88. Chapter 72 Vaccines for Healthcare Personnel - p. 1469 89. Chapter 73 Vaccination of Pregnant Women - p. 1489 90. Section V Public Health and Regulatory Issues - p. 1502.e6 91. Chapter 74 Immunization in the United States - p. 1503 92. Chapter 75 Immunization in Europe - p. 1523 93. Chapter 76 Immunization and Vaccine-Preventable Diseases in the Asia-Pacific Region - p. 1560 94. Chapter 77 Immunization in Low- and Middle-Income Countries - p. 1578 95. Chapter 78 Community Protection - p. 1603 96. Chapter 79 Economic Analyses of Vaccine Policies - p. 1625 97. Chapter 80 Regulation and Testing of Vaccines in the US - p. 1640 98. Chapter 81 Regulation of Vaccines in Europe - p. 1660 99. Chapter 82 Regulation of Vaccines in Low- and Middle-Income Countries - p. 1671 100. Chapter 83 Vaccine Safety - p. 1679 101. Chapter 84 Vaccine Hesitancy and Behavioral Factors Associated With Vaccine Uptake - p. 1696 102. Chapter 85 Legal Issues - p. 1704 103. Chapter 86 Ethics - p. 1738 104. Chapter 87 Vaccines to Prevent Mpox - p. e.1 105. Appendix Websites and Applications for Mobile Devices With Information About Immunization - p. 1745 106. Index - p. 1752
